Open Access
| Issue |
BIO Web Conf.
Volume 233, 2026
9th International Conference on Advances in Biosciences and Biotechnology: Emerging Innovations in Biomedical and Bioengineering Sciences (ICABB 2026)
|
|
|---|---|---|
| Article Number | 01005 | |
| Number of page(s) | 17 | |
| Section | Biomedical and Health Innovations | |
| DOI | https://doi.org/10.1051/bioconf/202623301005 | |
| Published online | 23 April 2026 | |
- B. Balakrishnan, S. S. Arul, A. Ravindran, and S. Venkataraman, “Brain Virome in Neurodegenerative Disorders: Insights from Transcriptomic Data Analysis,” ACS Chem Neurosci, vol. 14, no. 22, pp. 3979–3985, Nov. 2023, doi: 10.1021/acschemneuro.3c00432. [Google Scholar]
- X. Dang, B. A. Hanson, Z. S. Orban, M. Jimenez, S. Suchy, and I. J. Koralnik, “Characterization of the brain virome in human immunodeficiency virus infection and substance use disorder,” PLOS ONE, vol. 19, no. 4, p. e0299891, Apr. 2024, doi: 10.1371/journal.pone.0299891. [Google Scholar]
- P. Leblanc and I. M. Vorberg, “Viruses in neurodegenerative diseases: More than just suspects in crimes,” PLOS Pathogens, vol. 18, no. 8, p. e1010670, Aug. 2022, doi: 10.1371/journal.ppat.1010670. [Google Scholar]
- P. Wongchitrat, T. Chanmee, and P. Govitrapong, “Molecular Mechanisms Associated with Neurodegeneration of Neurotropic Viral Infection,” Mol Neurobiol, vol. 61, no. 5, pp. 2881–2903, May 2024, doi: 10.1007/s12035-023-03761-6. [Google Scholar]
- P. Kettunen, J. Koistinaho, and T. Rolova, “Contribution of CNS and extra-CNS infections to neurodegeneration: a narrative review,” Journal of Neuroinflammation, vol. 21, no. 1, p. 152, Jun. 2024, doi: 10.1186/s12974-024-03139-y. [Google Scholar]
- L. M. O’Connor, B. A. O’Connor, S. B. Lim, J. Zeng, and C. H. Lo, “Integrative multi-omics and systems bioinformatics in translational neuroscience: A data mining perspective,” Journal of Pharmaceutical Analysis, vol. 13, no. 8, pp. 836–850, Aug. 2023, doi: 10.1016/j.jpha.2023.06.011. [Google Scholar]
- J. A. Santiago, V. Bottero, and J. A. Potashkin, “Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology,” Front. Aging Neurosci., vol. 9, May 2017, doi: 10.3389/fnagi.2017.00166. [Google Scholar]
- A. Arif, P. Garg, and P. Srivastava*, “Microbiome-Gut-Brain Axis: AI Insights,” Insights in Biology and Medicine, vol. 8, no. 1, pp. 001–010, Jun. 2024, doi: 10.29328/journal.ibm.1001027. [Google Scholar]
- Z. He et al., “Single-cell transcriptomics analysis of cellular heterogeneity and immune mechanisms in neurodegenerative diseases,” Eur J Neurosci, vol. 59, no. 3, pp. 333–357, Feb. 2024, doi: 10.1111/ejn.16242. [Google Scholar]
- Y. Fangma, M. Liu, J. Liao, Z. Chen, and Y. Zheng, “Dissecting the brain with spatially resolved multi- omics,” J Pharm Anal, vol. 13, no. 7, pp. 694–710, Jul. 2023, doi: 10.1016/j.jpha.2023.04.003. [Google Scholar]
- A. Sait, C. Angeli, A. J. Doig, and P. J. R. Day, “Viral Involvement in Alzheimer’s Disease,” ACS Chem Neurosci, vol. 12, no. 7, pp. 1049–1060, Apr. 2021, doi: 10.1021/acschemneuro.0c00719. [Google Scholar]
- K. Bovis, M. Davies-Branch, and P. J. R. Day, “Dysregulated Neurotransmission and the Role of Viruses in Alzheimer’s Disease,” ACS Chem Neurosci, vol. 16, no. 6, pp. 982–987, Mar. 2025, doi: 10.1021/acschemneuro.4c00763. [Google Scholar]
- M. B. Mielcarska and B. T. Rouse, “Viruses and the Brain—A Relationship Prone to Trouble,” Viruses, vol. 17, no. 2, p. 203, Jan. 2025, doi: 10.3390/v17020203. [Google Scholar]
- Z. Rahic, E. Buratti, and S. Cappelli, “Reviewing the Potential Links between Viral Infections and TDP-43 Proteinopathies,” International Journal of Molecular Sciences, vol. 24, no. 2, p. 1581, Jan. 2023, doi: 10.3390/ijms24021581. [Google Scholar]
- G. Douaud et al., “SARS-CoV-2 is associated with changes in brain structure in UK Biobank,” Nature, vol. 604, no. 7907, pp. 697–707, Apr. 2022, doi: 10.1038/s41586-022-04569-5. [Google Scholar]
- I. R. Humphreys et al., “Protein interactions in human pathogens revealed through deep learning,” Nat Microbiol, vol. 9, no. 10, pp. 2642–2652, Oct. 2024, doi: 10.1038/s41564-024-01791-x. [Google Scholar]
- D. Morselli Gysi et al., “Network medicine framework for identifying drug-repurposing opportunities for COVID-19,” Proceedings of the National Academy of Sciences, vol. 118, no. 19, p. e2025581118, May 2021, doi: 10.1073/pnas.2025581118. [Google Scholar]
- N. Siminea et al., “Network analytics for drug repurposing in COVID-19,” Brief Bioinform, vol. 23, no. 1, p. bbab490, Jan. 2022, doi: 10.1093/bib/bbab490. [Google Scholar]
- Y. Zhou, Y. Hou, J. Shen, Y. Huang, W. Martin, and F. Cheng, “Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2,” Cell Discov, vol. 6, no. 1, p. 14, Mar. 2020, doi: 10.1038/s41421-020-0153-3. [Google Scholar]
- C. Vicidomini, F. Fontanella, T. D’Alessandro, and G. N. Roviello, “A Survey on Computational Methods in Drug Discovery for Neurodegenerative Diseases,” Biomolecules, vol. 14, no. 10, p. 1330, Oct. 2024, doi: 10.3390/biom14101330. [Google Scholar]
- K. S. Levine et al., “Virus exposure and neurodegenerative disease risk across national biobanks,” Neuron, vol. 111, no. 7, pp. 1086–1093.e2, Apr. 2023, doi: 10.1016/j.neuron.2022.12.029. [Google Scholar]
- D. E. Gordon et al., “A SARS-CoV-2 protein interaction map reveals targets for drug repurposing,” Nature, vol. 583, no. 7816, pp. 459–468, Jul. 2020, doi: 10.1038/s41586-020-2286-9. [Google Scholar]
- J. Abramson et al., “Accurate structure prediction of biomolecular interactions with AlphaFold 3,” Nature, vol. 630, no. 8016, pp. 493–500, Jun. 2024, doi: 10.1038/s41586-024-07487-w. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.